Latest news

• MHRA suspends new prescriptions of fibroid drug Esmya

  In December, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) started a review of the treatment for abnormal bleeding in women with uterine fibroids after four cases of serious liver injury - ... Esmya (ulipristal acetate) is a selective

• Joerg Moeller to head Bayer R&D after operational shake-up

  testing, vericiguat and neladenoson bialanate for heart failure, and progress in gynaecology with six candidates in clinical development for uterine fibroids and endometriosis.

• Bayer moves vilaprisan into phase III trials for uterine fibroids

  Bayer moves vilaprisan into phase III trials for uterine fibroids. ASTEROID study will investigate safety and efficacy of the novel drug. ... Uterine fibroids are the most common benign gynecological tumors, with approximately 5-10% of women requiring

• Astellas agrees €800m deal to buy Belgian biotech Ogeda

  The drug is also in development for polycystic ovary syndrome - with a phase IIa study in progress - as well as uterine fibroids, and the company is also considering developing it for

• Xarelto and Eylea continue to dominate Bayer's pharma sales

  They include five candidates in phase III trials: copanlisib for non-Hodgkin lymphoma, ODM-201 for hormone-sensitive prostate cancer, finerenone for diabetic kidney disease, vilaprisan for uterine fibroids and endriametosis